Drugs and Devices

FDA approves new daily treatment for RLS

The U.S. Food and Drug Administration has approved Horizant Extended Release Tablets (gabapentin enacarbil) as a daily treatment for moderate-to-severe restless legs syndrome (RLS). Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm250188.htm.

Related Articles:

Leave a Reply

You have to agree to the comment policy.